Examining Issues Related to Competition in the Pharmaceutical Marketplace: A Review of the FTC Report, Generic Drug Entry Prior to Patent Expiration: Hearing Before the Committee on Energy & Commerce, U.S. House of Representatives

Home > Diane Publishing Books >

Our Price: $35.00

Year: 2002
Pages: 142
Binding Paperback

Product Code: 0756742196

Description

Michael Bilirakis (ed). Hearing on whether innovator drug companies may be using questionable tactics to delay the entry of generic competitors. Witnesses: Mark A. Barondess; Lester M. Crawford, Acting Commr., & Daniel D. Troy, Chief Counsel, Food & Drug Admin. (FDA); Gregory J. Glover, Ropes & Tray, on behalf of PhRMA; Kathleen D. Jaeger, Pres. & CEO, Generic Pharmaceutical Assoc.; Sharon Levine, Assoc. Exec. Dir., the Permanente Medical Group, on behalf of RxHealthValue; & Timothy J. Muris, Chmn., Fed. Trade Comm. (FTC).

Share your knowledge of this product with other customers... Be the first to write a review